.
MergerLinks Header Logo

Announced

Completed

Avista-backed Acino completed the acquisition of Takeda Pharmaceutical's drug portfolio for $200m.

Financials

Edit Data
Transaction Value£159m
Consideration TypeCash
Capital Owned-
Capital Bid For100%
EV/Sales-
EV/EBITDA-
Share Price Premium-
One Off Charge-

Tags

Edit

Pharmaceuticals

Acquisition

prescription pharmaceutical

prescription pharmaceuticals

Majority

Friendly

Private

Single Bidder

Ukraine

Completed

Cross Border

Private Equity

Synopsis

Edit

Avista-backed Acino, a Swiss pharmaceutical company, completed the acquisition of the drug portfolio of Takeda Pharmaceutical in EMEA, a global, R&D-driven biopharmaceutical firm, for $200m. This is the third transaction in FY19 that furthers Takeda’s strategy to focus on business areas core to its long-term growth and facilitate rapid deleveraging following its acquisition of Shire. “The divestment of non-core assets sold in NEMEA represents the continued execution of our strategy to optimize our portfolio, invest in the defined core business areas, and accelerate our progress toward reaching our target leverage ratio,” Costa Saroukos, Takeda Chief Financial Officer.

© COPYRIGHT 2024 MERGERLINKS LIMITED.

ALL RIGHTS RESERVED.

15 BONHILL STREET, LONDON, EC2A 4DN, UNITED KINGDOM.

CONTACT US